Company: DNLI
Filing Date: 2025-04-17
Form Type: DEF 14A
Source: 0001714899-25-000087
Chunk: 83

Company: Denali Therapeutics Inc.
Filing Date: 2025-04-17
Form: DEF 14A
Chunk 83
---
 issued as compensation for his service on the Board and the funds affiliated with Baker Bros. Advisors LP are entitled to an indirect proportionate pecuniary interest in the securities. Julian C. Baker, Felix J. Baker, Baker Bros. Advisors LP and Baker Bros. Advisors (GP) LLC disclaim beneficial ownership except to the extent of their pecuniary interest therein.

(19) Consists of (i) 10,862,703 shares beneficially owned by our current executive officers, directors, and director nominees and (ii) 3,699,790 shares issuable upon the exercise of options exercisable and RSUs lapsing within 60 days of March 31, 2025, all of which will vest within such date.

<div align='center'>-61-</div>

### RELATED PERSON TRANSACTIONS
We describe below transactions and series of similar transactions, since the beginning of our last fiscal year, to which we were a party or will be a party, in which:

• the amounts involved exceeded or will exceed $120,000; and

• any of our directors, nominees for director, executive officers or beneficial holders of more than 5% of our outstanding capital stock, or any immediate family member of, or person sharing the household with, any of these individuals or entities (each, a related person), had or will have a direct or indirect material interest.

Securities Purchase Agreement Involving the Baker Funds

In February 2024, we entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers named therein, including Baker Brothers Life Sciences, L.P. and 667, L.P.. Under the Purchase Agreement, we agreed to sell 3,244,689 shares of our common stock for a purchase price of $17.07 per share, and 26,046,065 pre-funded warrants to purchase our common stock for a purchase price of $17.06 per share of common stock issuable upon exercise, for aggregate gross proceeds of approximately $500.0 million. The Baker Funds purchased all 26,046,065 pre-funded warrants for approximately $444.0 million.

In connection with the Purchase Agreement, we entered into a nominating agreement (the “Nominating Agreement”) with the Baker Funds. Pursuant to the Nominating Agreement, at such time beginning 60 days after the Baker Funds, together with their affiliates, beneficially own more than 10% of our outstanding common stock, and ending at such time as the Baker Funds and their